Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 14/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.42 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044652 | 0.91 | REN (0.55) | RENBACE1KLK5CYSLTR2CYSLTR1 | |
| SCHEMBL6044435 | 0.87 | KLK5 (0.45) | BACE1KLK5APPPSEN1PSEN2 | |
| SCHEMBL14003962 | 0.82 | REN (0.45) | RENBACE1KLK5CYSLTR2CYSLTR1 | |
| SCHEMBL6044314 | 0.80 | REN (0.57) | RENKLK5 | |
| SCHEMBL8262529 | 0.80 | REN (0.47) | RENBACE1KLK5APPPSEN1 | |
| SCHEMBL6044566 | 0.80 | REN (0.51) | RENBACE1KLK5APPPSEN1 | |
| SCHEMBL6044281 | 0.80 | REN (0.54) | RENBACE1KLK5PSEN1PSEN2 | |
| SCHEMBL6044411 | 0.80 | REN (0.54) | RENBACE1KLK5PSEN1PSEN2 | |
| SCHEMBL6044691 | 0.79 | ALOX15 (0.44) | RENKLK5 | |
| SCHEMBL6045224 | 0.79 | ALOX15 (0.44) | RENKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | ELAN PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154926-A1 | Methods of treating alzheimer's disease using aryl alkanoic acid amides | BACE1, APP, PSEN1 | REN 970/4885BACE1 1/4885KLK5 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.